Theseus Pharmaceuticals
  • Contact
  • Company
    • About Us
    • Leadership
    • Contact
  • Science
    • Our Approach
    • Disease Focus
    • Publications & Posters
  • Pipeline
    • Pipeline
    • KIT Program for GIST
    • EGFR Program for NSCLC
    • Discovery Program
    • Expanded Access Policy
  • Join Us
    • Our Culture
    • Open Roles
    • Diversity Commitment
  • Investors & Media
    • Corporate Profile
    • News & Events
      • News Releases
      • Events
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • SEC Filings
    • Corporate Governance
      • Corporate Governance
      • Leadership Team
      • Board of Directors
      • Board Committees
    • Investor Resources
      • Investor FAQs
      • Investor Alerts
Select Page
Theseus Pharmaceuticals
    • Company
      • About Us
      • Leadership
      • Contact
    • Science
      • Our Approach
      • Disease Focus
      • Publications & Posters
    • Pipeline
      • Pipeline
      • KIT Program for GIST
      • EGFR Program for NSCLC
      • Discovery Program
      • Expanded Access Policy
    • Join Us
      • Our Culture
      • Open Roles
      • Diversity Commitment
    • Investors & Media
      • Corporate Profile
      • News & Events
        • News Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
      • SEC Filings
      • Corporate Governance
        • Corporate Governance
        • Leadership Team
        • Board of Directors
        • Board Committees
      • Investor Resources
        • Investor FAQs
        • Investor Alerts
Header_Image_Investors
Board Committees
Compensation Committee

Description of Compensation Committee

Compensation Committee Charter
Compensation Committee Charter
140 KB
  • Chair
    Chair
    Don Hayden
  • Member
    Member
    Kathy Yi
  • Member
    Member
    Steven Stein
Corporate Communications Contact

Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

Investor Contact

Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com

Footer logo

Company

  • About Us
  • Leadership
  • Contact

Science

  • Our Approach
  • Disease Focus
  • Publications & Posters

Programs

  • Pipeline
  • KIT Program
  • EGFR Program
  • Discovery Program
  • Expanded Access Policy

Join Us

  • Our Culture
  • Open Roles
  • Diversity Commitment

Investors

  • Corporate Profile
  • News & Events
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Resources
Footer logo
© 2023 Theseus Pharmaceuticals. All rights reserved.
  • Privacy Policy
  • Terms of Use